alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 226–250 of 445 studies published 2022 · free to read (page 10 of 18) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 445 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Relational Design for Dementia and Job Significance (ReDeSign): Study protocol for a randomized controlled trial of an online dementia training for retail workers

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Contemporary Clinical Trials Communications 2022-01-20

ReDeSign provides dementia training to convenience store workers and contributes to developing an inclusive community for people with dementia. 1 key finding →

Design: randomized controlled trial Participants: 62 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Catastrophic health expenditure among Chinese adults living alone with cognitive impairment: findings from the CHARLS

✓ Peer-reviewed alzhub usefulness score 54 out of 100. BMC Geriatrics 2022-08-03

In comparison with participants living with others and with normal cognition, those adults living alone with cognitive impairment reported a higher percentage of catastrophic health expenditure (19.5% vs. 11.8%, respectively, P < 0.001). 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Brain communications 2022-05-24

Higher grey matter volumes/cortical thickness and fluorodeoxyglucose uptake have been consistently found in cognitively unimpaired individuals with abnormal Alzheimer's disease biomarkers compared with those with normal biomarkers. 4 key findings →

Participants: 319 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Medicina (Kaunas, Lithuania) 2022-03-16

Higher sNfL concentrations were associated with worse performance in cognitive tests at baseline, including CERAD (B = −10.084, SE = 2.999, p < 0.001) and MMSE (B = −3.014, SE = 1.293, p = 0.021). 3 key findings →

Design: cross-sectional Participants: 237 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The cost of inaction on physical inactivity to public health-care systems: a population-attributable fraction analysis

✓ Peer-reviewed alzhub usefulness score 53 out of 100. The Lancet. Global health 2022-12-05

499·2 million new cases of preventable major NCDs would occur globally by 2030 if the prevalence of physical inactivity does not change, with direct health-care costs of INT$520 billion. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's research & therapy 2022-04-26

These findings suggest that the loss of perivascular AQP4 localization may contribute to the development of AD pathology in human populations. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2022-02-24

The Alzheimer's Association hosted the second Latinos & Alzheimer's Symposium in May 2021. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Molecular neurodegeneration 2022-12-27

Higher soluble plasma p-tau levels may be the result of an intersection between insoluble deposits of amyloid-β and tau accumulation in brain, and may be associated with locus coeruleus degeneration. 3 key findings →

Participants: 35 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Human neural cell type-specific extracellular vesicle proteome defines disease-related molecules associated with activated astrocytes in Alzheimer's disease brain

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of extracellular vesicles 2022-01-01

In neurodegenerative diseases, extracellular vesicles (EVs) transfer pathogenic molecules and are consequently involved in disease progression. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Immunity 2022-12-14

Obesity-induced chronic liver inflammation is a hallmark of nonalcoholic steatohepatitis (NASH)-an aggressive form of nonalcoholic fatty liver disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Nature communications 2022-10-13

Cribriform prostate cancer, found in both invasive cribriform carcinoma (ICC) and intraductal carcinoma (IDC), is an aggressive histological subtype that is associated with progression to lethal disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MIND diet and the risk of dementia: a population-based study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's research & therapy 2022-01-12

Adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been linked to a decreased risk of dementia, but reverse causality and residual confounding by lifestyle may partly account for this link. 4 key findings →

Participants: 5,375 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cholesterol metabolism in aging simultaneously altered in liver and nervous system

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Aging 2022-02-07

In humans, aging, triggers increased plasma concentrations of triglycerides, cholesterol, low-density lipoproteins and lower capacity of high-density lipoproteins to remove cellular cholesterol. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of serum 25-hydroxyvitamin D concentrations with risk of dementia among individuals with type 2 diabetes: A cohort study in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 53 out of 100. PLoS medicine 2022-01-13

However, due to the synergistic effect between diabetic pathology and neuroinflammation, and the prothrombotic profile in patients with diabetes, whether vitamin D is associated with risk of dementia among patients with diabetes is unclear. 4 key findings →

Participants: 13,486 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2022-06-01

Imaging of amyloid deposition using PET has been available in research studies for 2 decades and has been approved for clinical use by the U.S. Food and Drug Administration, the European Medicines Agency, and other regulatory agencies around the world. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Molecular neurodegeneration 2022-02-02

This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation of Aβ plaques as well as on certain Aβ-associated downstream effects. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CSF phosphorylated tau as an indicator of subsequent tau accumulation

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurobiology of aging 2022-05-26

We evaluated the relationship between baseline CSF p-tau181 and the rate of tau PET change in the temporal meta-ROI and entorhinal cortex (ERC) and how it varied by amyloid level (CSF Aβ42 or amyloid PET) among 143 individuals from the Mayo Clinic Study of Aging and Mayo Alzheimer Disease Research Center. 3 key findings →

Design: longitudinal study Participants: 143 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Journal of clinical investigation 2022-12-15

BACKGROUNDSoluble triggering receptor expressed on myeloid cells 2 (sTREM2) plays an important role in the clearance of pathological amyloid-β (Aβ) in Alzheimer's disease (AD). 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events